Next Article in Journal
Development of a Sensitive and Stereoselective HPLC Method for the Analysis of Pindolol in Plasma and Pharmaceutical Products Using a Chiralpak IB Column and Fluorescence Detection
Previous Article in Journal
Synthesis of Novel 1,3-Diacetoxy-Acridones as Cytotoxic Agents and their DNA-Binding Studies
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Insight into the Structural Requirement of 2-Alkyl-4-(biphenylmethoxy)quinolines as Nonpeptide Angiotensin II Receptor Antagonists: A QSAR Approach

by
Vivek K. VYAS
1,*,
Anurekha JAIN
2,
Suresh C. MAHAJAN
1,
Radheshyam PATIDAR
1,
Sunil MISTRY
1 and
Subhash C. CHATURVEDI
3
1
Mahakal Institute of Pharmaceutical Studies, Rajiv Gandhi Technical University Behind Air Strip Datana Deaws Road Ujjain 456664 (M.P.) India
2
B. R. Nahata College of Pharmacy, Department of Medicinal Chemistry, Rajiv Gandhi Technical University, Mhow-Neemuch Road 458001 Mandsaur (M.P.) India
3
School of Pharmacy Devi Ahilya Vishwavidylaya, Takshashila Parisar Khandwa road, 452003 Indore (M.P.) India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2009, 77(1), 33-46; https://doi.org/10.3797/scipharm.0810-01
Submission received: 10 October 2008 / Accepted: 13 January 2009 / Published: 14 January 2009

Abstract

In the current study a quantitative structure activity relationship approach using sequential multiple linear regression analysis was applied to a series of 2-alkyl- 4-(biphenylylmethoxy)quinolines as angiotensin II (Ang II) receptor antagonists by using Chem 3D and Dragon Software. The studies, carried out on 33 analogs, give statistically significant correlations of selective Ang II antagonistic activity with physical properties concerning size, symmetry, shape and distribution of molecule atoms. Among several 2D quantitative structure activity relationship models, one model gave good statistical significance (r > 0.81, Ftest = 10.47, S < 0.30, chance correlation < 0.01). 3D QSAR studies show that Hennery’s law constant, Dipole and VDWE play a significant role in Ang II antagonistic activity. These QSAR studies help us in the design and prediction of novel substituted benzimidazole Ang II receptor antagonists.
Keywords: QSAR; Angiotensin II antagonists; Hypertension; AT1 and AT2 receptor QSAR; Angiotensin II antagonists; Hypertension; AT1 and AT2 receptor

Share and Cite

MDPI and ACS Style

VYAS, V.K.; JAIN, A.; MAHAJAN, S.C.; PATIDAR, R.; MISTRY, S.; CHATURVEDI, S.C. Insight into the Structural Requirement of 2-Alkyl-4-(biphenylmethoxy)quinolines as Nonpeptide Angiotensin II Receptor Antagonists: A QSAR Approach. Sci. Pharm. 2009, 77, 33-46. https://doi.org/10.3797/scipharm.0810-01

AMA Style

VYAS VK, JAIN A, MAHAJAN SC, PATIDAR R, MISTRY S, CHATURVEDI SC. Insight into the Structural Requirement of 2-Alkyl-4-(biphenylmethoxy)quinolines as Nonpeptide Angiotensin II Receptor Antagonists: A QSAR Approach. Scientia Pharmaceutica. 2009; 77(1):33-46. https://doi.org/10.3797/scipharm.0810-01

Chicago/Turabian Style

VYAS, Vivek K., Anurekha JAIN, Suresh C. MAHAJAN, Radheshyam PATIDAR, Sunil MISTRY, and Subhash C. CHATURVEDI. 2009. "Insight into the Structural Requirement of 2-Alkyl-4-(biphenylmethoxy)quinolines as Nonpeptide Angiotensin II Receptor Antagonists: A QSAR Approach" Scientia Pharmaceutica 77, no. 1: 33-46. https://doi.org/10.3797/scipharm.0810-01

APA Style

VYAS, V. K., JAIN, A., MAHAJAN, S. C., PATIDAR, R., MISTRY, S., & CHATURVEDI, S. C. (2009). Insight into the Structural Requirement of 2-Alkyl-4-(biphenylmethoxy)quinolines as Nonpeptide Angiotensin II Receptor Antagonists: A QSAR Approach. Scientia Pharmaceutica, 77(1), 33-46. https://doi.org/10.3797/scipharm.0810-01

Article Metrics

Back to TopTop